Explore real-world semaglutide dosage trends, reconstitution volumes, and vial size patterns from 20,000+ anonymized WPA peptide calculator sessions.
Aggregated from thousands of anonymized reconstitution sessions, this data shows how peptide researchers approach semaglutide dosing—from common weekly dose targets and preferred vial sizes to bacteriostatic water volumes used with this GLP-1 receptor agonist.
Semaglutide is one of the most studied peptides in modern endocrinology, and the trials behind it cover three different formulations and two different cadences. 4mg weekly dose and reported roughly a 20% reduction in major adverse cardiovascular events over about 39 months). 0mg. The oral side—Rybelsus, evaluated in the PIONEER program—uses a fundamentally different formulation built around a SNAC absorption enhancer and is dosed daily at 3mg, 7mg, or 14mg. Across every published injectable trial, the cadence is once weekly; daily dosing exists only in oral form.
Semaglutide is the GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus, and one of the most-sourced research peptides for weight-management and metabolic studies. It ships as a lyophilized powder reconstituted with bacteriostatic water before use.
Semaglutide binds the GLP-1 receptor with high affinity, amplifying glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers. A fatty-acid sidechain enables albumin binding, extending the half-life to roughly 7 days and supporting once-weekly subcutaneous dosing.
The SUSTAIN program established efficacy in type 2 diabetes, STEP-1 (Wilding et al., NEJM 2021) reported ~14.9% mean weight reduction at 68 weeks in adults with obesity at 2.4mg weekly, and SELECT (Lincoff et al., NEJM 2023) showed a 20% reduction in major adverse cardiovascular events in adults with established CVD and overweight/obesity. FLOW reported kidney-outcome benefits in T2D with chronic kidney disease.
Semaglutide has a reported half-life of ~7 days, and the dose intervals researchers model most often fall around once weekly. Once-weekly dosing reaches steady state in about 5 weeks. With a 7-day half-life dosed every 7 days, your trough level ends up roughly equal to a single dose, and your peak roughly doubles it. It is catalogued under Weight Loss on WPA.
5,134 Semaglutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (1,023 calculations). The median dose across all sessions is 500mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (2,016 sessions). The most common dosing frequency is once weekly (534 logged protocols), followed by daily (7x/week) (46).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.